Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INC Research Holdings Inc (INCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: INCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 19.36% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.22M USD | Price to earnings Ratio - | 1Y Target Price 33.56 |
Price to earnings Ratio - | 1Y Target Price 33.56 | ||
Volume (30-day avg) - | Beta 0.58 | 52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 |
52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.39% | Operating Margin (TTM) -86.82% |
Management Effectiveness
Return on Assets (TTM) -7.09% | Return on Equity (TTM) -17.03% |
Valuation
Trailing PE - | Forward PE 6.94 | Enterprise Value 120187421 | Price to Sales(TTM) 0.34 |
Enterprise Value 120187421 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 5.29 | Shares Outstanding 54512600 | Shares Floating 27296363 |
Shares Outstanding 54512600 | Shares Floating 27296363 | ||
Percent Insiders 30.2 | Percent Institutions 5.38 |
Upturn AI SWOT
INC Research Holdings Inc
Company Overview
History and Background
INC Research Holdings Inc. was a global contract research organization (CRO) founded in 1985. It provided clinical development services to the pharmaceutical, biotechnology, and medical device industries. In 2017, INC Research merged with inVentiv Health to form Syneos Health (SYNH).
Core Business Areas
- Clinical Development: Comprehensive clinical trial services, including trial design, site selection, patient recruitment, data management, and regulatory submissions.
- Medical Affairs: Services related to post-marketing studies, medical information, and medical communications.
Leadership and Structure
Before the merger, INC Research was led by a CEO and executive team. The organizational structure was typical of a CRO, with functional departments such as clinical operations, medical affairs, and data management.
Top Products and Market Share
Key Offerings
- Phase I-IV Clinical Trials: Management and execution of clinical trials across all phases of drug development. Competitors included Quintiles (now IQVIA), Covance (now Labcorp), and PPD (now Thermo Fisher Scientific).
- Central Laboratory Services: Laboratory testing and analysis services for clinical trials. Competitors included Labcorp and Quest Diagnostics.
Market Dynamics
Industry Overview
The CRO industry is characterized by increasing outsourcing from pharmaceutical and biotechnology companies seeking to reduce costs and accelerate drug development. The market is competitive with large, global players and smaller, niche providers.
Positioning
INC Research aimed to be a leading CRO, known for its therapeutic expertise and customer service. Its competitive advantage was its focus on certain therapeutic areas and its ability to provide customized solutions.
Total Addressable Market (TAM)
The global CRO market is valued in the hundreds of billions of dollars. INC Research was positioned to capture a portion of this TAM through its clinical development services.
Upturn SWOT Analysis
Strengths
- Strong therapeutic expertise
- Global reach
- Customer-centric approach
- Experienced management team
Weaknesses
- Reliance on key clients
- Competition from larger CROs
- Integration risks with acquisitions
- Price pressures
Opportunities
- Increased outsourcing by pharmaceutical companies
- Growth in emerging markets
- Expansion into new therapeutic areas
- Adoption of new technologies
Threats
- Economic downturns
- Regulatory changes
- Competition from other CROs
- Loss of key clients
Competitors and Market Share
Key Competitors
- IQV
- LH
- TMO
Competitive Landscape
INC Research was a mid-sized CRO competing with larger and smaller players. Its competitive advantage was its therapeutic expertise and customer service.
Major Acquisitions
Acurian
- Year: 2014
- Acquisition Price (USD millions): 365
- Strategic Rationale: Expanded patient recruitment capabilities and geographic reach.
Growth Trajectory and Initiatives
Historical Growth: INC Research experienced growth through organic expansion and acquisitions. Its growth was driven by the increasing demand for outsourced clinical development services.
Future Projections: Future projections for INC Research as a standalone company are no longer applicable, as it is now part of Syneos Health.
Recent Initiatives: Recent initiatives before the merger included expanding its geographic reach, investing in new technologies, and focusing on strategic partnerships.
Summary
INC Research, before merging into Syneos Health, was a mid-sized CRO leveraging expertise and customer relationships. While it showed considerable growth, competition remained intense, and it faced risks from client concentration and market fluctuations. Its acquisition by Syneos Health was a strategic move to broaden capabilities and market presence. Careful execution would be required to realize the full benefits of the merger. Overall, INC Research was a solid company in a growing industry, that sought the value of merging into a larger organization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (prior to merger)
- Company Website (prior to merger)
- Industry Reports
- Market Analysis Reports
Disclaimers:
This analysis is based on publicly available information and historical data prior to INC Research's merger with inVentiv Health to form Syneos Health. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INC Research Holdings Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-11-07 | CEO & Chairman Mr. Alexander Rabinovich | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 320 | Website https://www.intercure.co |
Full time employees 320 | Website https://www.intercure.co | ||
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.